Drug Profile


Alternative Names: PM 94128

Latest Information Update: 10 Jul 2007

Price : $50

At a glance

  • Originator PharmaMar
  • Class Antineoplastics; Coumarins; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 07 Oct 2004 Preclinical trials in Cancer in Spain (unspecified route)
  • 25 Apr 2002 Phase-I clinical trials in Cancer in Spain (unspecified route)
  • 07 Jul 1997 Preclinical development for Cancer in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top